ArticleFrontiers in cellular neuroscience2026
Efficacy of anticoagulation therapy in elderly patients with clinically diagnosed Alzheimer's disease and atrial fibrillation: a clinical outcomes study.
Article in Frontiers in cellular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Clinically diagnosed Alzheimer's disease (AD) and atrial fibrillation (AF) are prevalent in the elderly, and their co-occurrence presents a complex management dilemma, balancing stroke prevention against bleeding risks, particularly in the context of cognitive impairment. This real-world cohort study aimed to evaluate the clinical outcomes of anticoagulant therapy in elderly patients with AD and AF. Methods: We analyzed data from 342 patients (mean age 78.5 years; 58.3% female) with non-valvular AF and AD. Patients were categorized into anticoagulant ( Results: Anticoagulation was associated with a significantly lower incidence of ischemic stroke/systemic embolism (annualized rate 2.9% vs. 7.1%; hazard ratio [HR] = 0.35, 95% CI 0.17-0.73, Discussion: In conclusion, anticoagulation, particularly with DOACs, provides a favorable net clinical benefit by significantly reducing stroke and mortality without a marked increase in intracranial hemorrhage in elderly AD patients with AF, supporting its judicious use. Further prospective studies are warranted to refine personalized decision-making. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251271276, Identifier: CRD420251271276.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.